Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06723561 · ClinicalTrials.gov registry record · Phase 2
Treating Central Neuropathic Pain With Low Dose Naltrexone for People With Spinal Cord Injury
A Phase 2 study of Spinal Cord Injury and Central Neuropathic Pain, sponsored by Medical College of Wisconsin.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT06723561 is a Phase 2 study of Spinal Cord Injury and Central Neuropathic Pain that is actively recruiting participants, run by Medical College of Wisconsin. The registered enrollment target is 10 participants, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06723561, a Phase 2 study of Spinal Cord Injury and Central Neuropathic Pain, is actively recruiting participants, sponsored by Medical College of Wisconsin.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this pilot clinical trial is to find out how well low dose naltrexone works for people with pain due to spinal cord injury. The main questions it aims to answer are: will low dose naltrexone reduce pain, and increase the quality of life for people with central neuropathic pain due to spinal cord injury. Hypothesis 1: LDN will decrease the severity of CNP in adult patients with SCI as measured by the Neuropathic Pain Scale (NPS) Hypothesis 2: LDN will improve quality of life of patients with SCI as measured by various validated clinical tools There is no comparison group. This study is being completed to give investigators more information for how to best run a larger clinical trial. Participants will be asked to take an oral dose of 4.5mg of naltrexone, daily, for 12 weeks.
Conditions Studied
Interventions
- DRUG 4.5mg daily dose of naltrexone
Study Locations (1)
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2025-02-01 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06723561
The ClinicalTrials.gov registry entry for NCT06723561 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 86-participant average among 99 other Spinal Cord Injury trials with a reported enrollment target (88% lower). The listed sponsor is Medical College of Wisconsin, which has 447 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Spinal Cord Injury appearing as the primary indexed condition, and to 1 intervention - of which 4.5mg daily dose of naltrexone is the first listed.
NCT06723561 reports 1 study location spanning 1 distinct geographic area - top geographies include Wisconsin.
Frequently Asked Questions
What is clinical trial NCT06723561 about?
NCT06723561 is a clinical study titled "Treating Central Neuropathic Pain With Low Dose Naltrexone for People With Spinal Cord Injury". The goal of this pilot clinical trial is to find out how well low dose naltrexone works for people with pain due to spinal cord injury. The main questions it aims to answer are: will low dose naltrexone reduce pain, and increase the quality of life for people with central neuropathic pain due to spi...
What is the current status of trial NCT06723561?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2025-02-01. Estimated completion is 2026-12-31.
What conditions does trial NCT06723561 study?
This clinical trial studies the following conditions: Spinal Cord Injury, Central Neuropathic Pain.
What interventions are being tested in trial NCT06723561?
The interventions under investigation include: 4.5mg daily dose of naltrexone (DRUG).
Who is sponsoring clinical trial NCT06723561?
This trial is sponsored by Medical College of Wisconsin, which has 447 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06723561 being conducted?
This trial has 1 study location across Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Spinal Cord Injury
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Locomotor Training With Testosterone to Promote Bone and Muscle Health After Spinal Cord Injury
RECRUITING · Phase 2
-
CBD for Lower Urinary Tract Dysfunction in Spinal Cord Injury
RECRUITING · Phase 2
-
Electrical Control of Bladder in Spinal Cord Injury Patients
COMPLETED · Phase 2
-
Effects of Electrical Stimulation and Vitamin D Supplementation on Bone Health Following Spinal Cord Injury.
COMPLETED · Phase 2
-
Clinical Neuropharmacology of Pain in Spinal Cord Injury- Dextromethorphan/Lidocaine Combination Clinical Trial
COMPLETED · Phase 2
-
Use of an Oral Beta-2 Agonist in Persons With Spinal Cord Injury
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.